General Neuroblastoma

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (05-23-2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (03-26-2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (07-15-2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Improved Survival with Busulphan-Melphalan Chemotherapy in Pediatric Neuroblastoma (06-8-2011)

Treatment with high doses of the chemotherapy combination including busulphan and melphalan significantly improves survival and reduces cancer progression among pediatric patients with high-risk neuroblastoma. These results were presented at a plenary... Continue Reading

Reduced Chemotherapy Regimen May Be Effective in Neuroblastoma (11-10-2010)

According to results of a Phase III clinical trial, patients with intermediate-risk neuroblastoma may be effectively treated with reduced doses of chemotherapy given over a shorter period. These findings were published in the New England Journal of Medicine. Neuroblastoma... Continue Reading

Hycamtin/Cyclophosphamide Delays Progression of Recurrent Neuroblastoma (09-13-2010)

Children with recurrent or refractory neuroblastoma experienced an improvement in progression-free survival when treated with the combination of Hycamtin® (topotecan) plus cyclophosphamide; overall survival, however, was not improved compared with Hycamtin... Continue Reading

Neuroblastoma Survival has Improved (05-12-2010)

Between 1979 and 2005, ten-year overall survival with neuroblastoma improved from 34.9% to 65%. The results of this study, conducted in Italy, were published in the Journal of Clinical Oncology. Neuroblastoma is a disease in which cancerous cells form... Continue Reading

Genetic Variation Associated with Risk of Neuroblastoma (03-8-2009)

Genetic Variation Associated with Risk of Neuroblastoma Individuals with a common genetic variation (change in DNA) on the chromosome band 6p22 have a significantly increased risk of developing neuroblastoma, as well as an increased risk for disease relapse... Continue Reading